{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:22:49Z","timestamp":1792581769904,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the efficacy and safety of prostaglandin E1 (PGE1) for the management of central\/branch retinal artery occlusion (CRAO\/BRAO).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Our protocol was registered prospectively on PROSPERO (CRD42024522961). We searched four electronic databases [PubMed, Scopus, Web of Science, and Google Scholar] to retrieve all studies reported using PGE1 for patients with CRAO\/BRAO. We conducted a Wilcoxon signed-rank test to assess the effect of PGE1 on the visual acuity (VA) of included subjects. VA change was used as a measure to assess the degree of VA improvement. We assessed the quality of included studies using the JBI tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We included a total of six studies with a total of 21 cases. Age ranged from 45 to 97 years with a mean of 65.76 years for 10 women and 11 men. Cases with CRAO represented 85.7% and BRAO represented 14.3% of total cases. The median time from symptoms onset to treatment initiation was 7 hours. The median for the initial dose was 40 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>g. The Wilcoxon signed-rank test revealed significant improvement in visual acuity after intravenous PGE1 treatment (V = 231, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our analysis revealed preliminary evidence suggesting that IV PGE1 may be a potentially safe and effective treatment for improving VA in patients with CRAO\/BRAO. However, our evidence is limited as our review relies primarily on case reports and case series.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004458","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T22:00:07Z","timestamp":1741730407000},"page":"1239-1246","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["THE EFFICACY AND SAFETY OF INTRAVENOUS PROSTAGLANDIN E1 IN THE MANAGEMENT OF RETINAL ARTERY OCCLUSION"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-2188","authenticated-orcid":false,"given":"Hashem Abu","family":"Serhan","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hamad Medical Corporations, Doha, Qatar;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Oweidah","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tanta University, Tanta, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla","family":"Shaheen","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami, Miami, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith O.","family":"Emoush","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hamad Medical Corporation, Doha, Qatar;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Bin","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tripoli University, Tripoli, Libya;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutaz","family":"Al-Nawaflh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory Eye Center, Emory University, Atlanta, Georgia;"},{"name":"Division of Ophthalmology, King Hussein Hospital, Jordanian Royal Medical Services, Amman, Jordan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman G.","family":"Elnahry","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami, Miami, Florida;"},{"name":"Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jamaneurol.2015.1578","article-title":"Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient-level meta-analysis","volume":"72","author":"Schrag","year":"2015","journal-title":"JAMA Neurol"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.04.001","article-title":"Ocular vascular occlusive disorders: natural history of visual outcome","volume":"41","author":"Hayreh","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","article-title":"An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Sacco","year":"2013","journal-title":"Stroke"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.ophtha.2018.03.054","article-title":"Management of acute retinal ischemia: follow the guidelines","volume":"125","author":"Biousse","year":"2018","journal-title":"Ophthalmology"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/STROKEAHA.115.010828","article-title":"Retinal artery occlusion and the risk of stroke development: twelve-year nationwide cohort study","volume":"47","author":"Rim","year":"2016","journal-title":"Stroke"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.10.11.2","article-title":"Risk of stroke, myocardial infarction, and death among patients with retinal artery occlusion and the effect of antithrombotic treatment","volume":"10","author":"Vestergaard","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40123-018-0126-x","article-title":"Ischemic stroke risk in medicare beneficiaries with central retinal artery occlusion: a retrospective cohort study","volume":"7","author":"French","year":"2018","journal-title":"Ophthalmol Ther"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1161\/STROKEAHA.120.033466","article-title":"Thrombolysis in mild stroke: a comparative analysis of the PRISMS and MaRISS studies","volume":"52","author":"Asdaghi","year":"2021","journal-title":"Stroke"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2147\/OPTH.S232560","article-title":"Intra-arterial thrombolysis for central retinal artery occlusion","volume":"13","author":"Hakim","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/S0161-6420(95)30758-0","article-title":"Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion","volume":"102","author":"Atebara","year":"1995","journal-title":"Ophthalmology"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2415-14-28","article-title":"Anterior chamber paracentesis after central retinal artery occlusion: a tenable therapy?","volume":"14","author":"Fie\u00df","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/OPTH.S121307","article-title":"Reversibility of retinal ischemia due to central retinal artery occlusion by hyperbaric oxygen","volume":"11","author":"Hadanny","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/01.ju.0000097496.27675.c4","article-title":"Mechanisms of prostaglandin E1-induced relaxation in penile resistance arteries","volume":"171","author":"Ruiz Rubio","year":"2004","journal-title":"J Urol"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0143-4160(03)00170-2","article-title":"Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1","volume":"35","author":"Fox","year":"2004","journal-title":"Cell Calcium"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00246-015-1251-0","article-title":"Long-term prostaglandin E1 infusion for newborns with critical congenital heart disease","volume":"37","author":"Aykanat","year":"2016","journal-title":"Pediatr Cardiol"},{"key":"R17-20250619","first-page":"474","article-title":"Intravenous infusion of prostaglandin E1 (PGE1) in management of limb ischemia","volume":"52","author":"Sethi","year":"1986","journal-title":"Am Surg"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00595-005-3116-2","article-title":"Effect of prostaglandin E1 on ischemia-reperfusion injury during abdominal aortic aneurysm surgery","volume":"36","author":"Sako","year":"2006","journal-title":"Surg Today"},{"issue":"5","key":"R19-20250619","first-page":"S5","article-title":"Intravenous prostaglandin E1 infusion for acute central retinal artery occlusion","volume":"50","author":"Malbin","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"e001014","DOI":"10.1136\/bmjophth-2022-001014","article-title":"Intravenous lipo-prostaglandin E1 administration for patients with acute central retinal artery occlusion","volume":"7","author":"Suzuki","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"issue":"4","key":"R21-20250619","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/ICB.0b013e3182051de9","article-title":"Branch retinal arterial occlusion treated with intravenous prostaglandin e1 and steroids","volume":"5","author":"Steigerwalt","year":"2011","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"R22-20250619","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1385\/AO:36:1:44","article-title":"Poor vision for 2 days\u2019 duration and rapid visual recovery after treatment in a patient with branch retinal artery occlusion","volume":"36","author":"Ikeda","year":"2004","journal-title":"Ann Ophthalmol"},{"issue":"1","key":"R23-20250619","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000533404","article-title":"Documented reperfusion of the retina on fluorescein angiography after administration of intravenous prostaglandin E1 for central retinal artery occlusion: a case report","volume":"14","author":"Chacko","year":"2023","journal-title":"Case Rep Ophthalmol"},{"issue":"4","key":"R24-20250619","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1167\/iovs.12-11445","article-title":"Systemic prostaglandin E1 to treat acute central retinal artery occlusion","volume":"54","author":"Takai","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000049415","article-title":"Effect of prostaglandin E1 on ophthalmic artery velocimetry in a pre-eclamptic woman with visual disturbance caused by retinal arterial narrowing","volume":"53","author":"Ohno","year":"2002","journal-title":"Gynecol Obstet Invest"},{"issue":"4","key":"R26-20250619","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/000331970305400415","article-title":"Acute branch retinal arterial embolism successfully treated with intravenous prostaglandin E1--case reports","volume":"54","author":"Steigerwalt","year":"2003","journal-title":"Angiology"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10654-019-00576-5","article-title":"A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research","volume":"35","author":"Muka","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.345441","article-title":"Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia","volume":"200","author":"Lefer","year":"1978","journal-title":"Science"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/01.CIR.64.5.893","article-title":"Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease","volume":"64","author":"Lewis","year":"1981","journal-title":"Circulation"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:04:18Z","timestamp":1750349058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004458"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004458","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}